SCHEMBL25220804

SCHEMBL25220804

O=C1NCCc2sc(-c3nc(Nc4cc5c(cc4C4CC4)CNCC5)ncc3C(F)(F)F)cc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K1 Q92918 1/20 0.38
▸ LRRK2 Q5S007 4/20 0.36
▸ PTK2 Q05397 2/20 0.35
▸ KIT P10721 1/20 0.34
▸ FLT3 P36888 1/20 0.34
▸ PTK2B Q14289 1/20 0.34
▸ CDC7 O00311 1/20 0.34
▸ DBF4 Q9UBU7 1/20 0.34
▸ CDK7 P50613 3/20 0.33
▸ CCNH P51946 3/20 0.33
▸ MNAT1 P51948 3/20 0.33
▸ CDK2 P24941 2/20 0.33
▸ CCNE1 P24864 1/20 0.33
▸ PARP1 P09874 2/20 0.33
▸ PARP2 Q9UGN5 2/20 0.33
▸ TYRO3 Q06418 2/20 0.32
▸ MERTK Q12866 2/20 0.32
▸ AXL P30530 1/20 0.32
▸ CCNT1 O60563 1/20 0.32
▸ CDK4 P11802 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30412783 1.00 MAP4K1 (0.38) MAP4K1LRRK2PTK2KITFLT3
SCHEMBL25204192 0.89 MAP4K1 (0.40) MAP4K1PTK2KITFLT3PTK2B
SCHEMBL30412493 0.89 MAP4K1 (0.40) MAP4K1PTK2KITFLT3PTK2B
SCHEMBL30413194 0.88 MAP4K1 (0.44) MAP4K1LRRK2PTK2CDC7DBF4
SCHEMBL25208001 0.88 MAP4K1 (0.44) MAP4K1LRRK2PTK2CDC7DBF4
SCHEMBL25210979 0.87 MAP4K1 (0.40) MAP4K1PTK2PTK2BCDC7DBF4
SCHEMBL30412210 0.87 MAP4K1 (0.40) MAP4K1PTK2PTK2BCDC7DBF4
SCHEMBL25207999 0.86 MAP4K1 (0.40) MAP4K1LRRK2PTK2KITFLT3
SCHEMBL30412258 0.86 MAP4K1 (0.40) MAP4K1LRRK2PTK2KITFLT3
SCHEMBL25205517 0.84 TYRO3 (0.38) LRRK2KITFLT3TYRO3MERTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. 2025-05-08 — — US disclosed
WO-2023215494-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-11-09 — — WO disclosed
WO-2023215494-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-11-09 — — WO disclosed
WO-2023087027-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-05-19 — — WO disclosed
WO-2023087027-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ULK1, ULK2, ULK3 MAP4K1 182/4885LRRK2 610/4885PTK2 1123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback